SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (598)8/1/1999 2:56:00 AM
From: Mike McFarland  Respond to of 4474
 
A few fun quotes from PNAS pp. 8657-8662

"Peak hGH levels after each administration were
remarkably consistent, with no detectable
reduction between the first dose and the last
dose 10 months after viral injection"

That just takes my breath away.

"...AAV, as opposed to adenovirus or naked DNA,
does not efficiently transduce antigen-presenting
cells"

"...the system performed essentially identically
in immunocompetent mice as in immunodeficient
animals"

"Importantly, in the absence of rapamycin, protein
expression is undetectable" (I assume that is the
same as saying the system is not leaky)

Capn' Midnight, signing out.



To: Mike McFarland who wrote (598)8/8/1999 10:11:00 PM
From: LLCF  Respond to of 4474
 
<If the conversion price fell even further, then more shares would be issuable>

Does anyone know the specifics of the death spiral??? I'll call the company if not, but perhaps someone has looked into it. We should know all about the strike price [downward floating I assume, ouch, but how many days average stock price is it] and how many shares of preferred are out and when expiration is.

DAK


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News